AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04241237 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Draw
Description: Blood will be drawn from each patient to check the concordance between liquid and tissue biopsy
Study NCT03769740 — intervention group
Intervention type: DEVICE
Intervention: Cerebral Oximetry
Description: Non invasive, near infrared spectroscopy cerebral oximetry
Study NCT04230486 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cross-model Visual Auditory Rehabilitation
Description: Subjects will put on a virtual reality rehabilitation system which will present sights and sounds.
Study NCT01148056 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy
Description: Radiation therapy once a day for 5 days
Study NCT02926573 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Study NCT02926573 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02186353 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Partial feeding study
Description: Provision of all grain foods where only the processing of kernels used to produce the grain foods will differ among test diets. Each participant will be assigned to complete the three 4-week test diets in random sequence.
Study NCT03143049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCD
Description: For PCD, patients will be treated as follows: PO pomalidomide 4mg from D1-21, PO cyclophosphamide 400mg on D1, 8 and 15, and PO or IV dexamethasone 40mg D1, 8, 15 and 22 in a 28-day cycle.~Patients will be assessed every 28 days (+/- 10 days). Patients shall receive the treatment until disease progression, unacceptable toxicity as determined by treating physician, withdrawal of consent or mortality (whichever occurs first).
Study NCT03143049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PD
Description: For PD, Patients will be treated as follows: PO pomalidomide 4mg from D1-21 and PO or IV dexamethasone 40mg D1, 8, 15 and 22 in a 28-day cycle.~Patients will be assessed every 28 days (+/- 10 days). Patients shall receive the treatment until disease progression, unacceptable toxicity as determined by treating physician, withdrawal of consent or mortality (whichever occurs first).
Study NCT00414726 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NBO (Normobaric Oxygen)
Description: High-flow oxygen delivered via a facemask. A total of 240 individuals with acute ischemic stroke will be randomized 1:1 to receive either room air or oxygen administered at 30-45 L/min via a simple facemask for 8 hours.
Study NCT00414726 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NBO (Normobaric Oxygen)
Description: High-flow oxygen delivered via a facemask. A total of 240 individuals with acute ischemic stroke will be randomized 1:1 to receive either room air or oxygen administered at 30-45 L/min via a simple facemask for 8 hours.
Study NCT02229903 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active DTMS Treatment
Description: H-coil Deep TMS 29 TMS treatments over 6 weeks.
Study NCT02229903 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Treatment
Description: 29 treatments over 6 weeks.
Study NCT02079285 — intervention group
Intervention type: PROCEDURE
Intervention: EUS-FNA
Study NCT03373513 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic single-site Hysterectomy
Description: Robotic assisted Periumbilical single incision hysterectomy
Study NCT00414726 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Room Air
Description: Room Air delivered via a facemask. A total of 240 individuals with acute ischemic stroke will be randomized 1:1 to receive either room air or oxygen administered at 30-45 L/min via a simple facemask for 8 hours.
Study NCT00414726 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Room Air
Description: Room Air delivered via a facemask. A total of 240 individuals with acute ischemic stroke will be randomized 1:1 to receive either room air or oxygen administered at 30-45 L/min via a simple facemask for 8 hours.
Study NCT00085501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cetuximab
Description: Arm 1: 400 mg/m2 (Initial dose), 2 hour IV infusion on Day 1, Week 1 only. 250 mg/m2 (Subsequent doses), 1 hour IV infusion, on Day 1 weekly starting at Week 2.~Arm 2: 400 mg/m2 (Initial dose), 2 hour IV infusion on Week 13 ONLY 250 mg/m2 (Subsequent doses), 1 hour IV infusion, weekly starting at Week 14.
Study NCT00085501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: Arm 1: AUC=6 30 minute IV infusion immediately following paclitaxel on Day 1 q 21 days x 4 starting at Week 2~Arm 2: AUC=6 30 minute IV infusion immediately following paclitaxel on Day 1 q 21 days x 4 starting at Week 1
Study NCT00085501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: Arm 1: 225 mg/m2 3 hour IV infusion 1 hour following cetuximab on Day 1, q 21 days x 4 Starting at Week 4.~Arm 2: 225 mg/m2 3 hour IV infusion 1 hour following cetuximab on Day 1, q 21 days x 4 Starting at Week 1.
Study NCT01598584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine plus gemcitabine
Description: Mirtazapine,15mg/day for 3 days, If patients is durable, the dosage increase to 30mg/day, if the patient is durable, the doctor then will decided whether to increase to 45mg. Gemcitabine 1000mg/M2,d1,d8,q3w
Study NCT01598584 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine, placebo
Description: Gemcitabine 1.0g/m2,d1,d8,q3w placebo
Study NCT03373513 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic hysterectomy
Description: Multiport laparoscopic hysterectomy
Study NCT00185614 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic cell transplant (Auto-HCT)
Description: The target cell dose is 2.6 x 10e6 CD34+ cells/kg
Study NCT00185614 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic cell transplant (Allo-HCT)
Description: The target cell dose is 5 x 10e6 CD34 cells/kg
Study NCT00185614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide administered intravenously (IV) at 4 mg /m² mobilize peripheral blood progenitor cells (PBPC) for autologous re-infusion
Study NCT00372996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-751,871
Description: CP-751,871 given at 20 mg/kg IV on day 1 of each 21 day cycle.
Study NCT00372996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane
Description: Exemestane given at 25 mg orally once a day.
Study NCT00372996 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exemestane
Description: Exemestane given at 25 mg orally once a day. Treatment until progression or toxicity
Study NCT00372996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Used for salvage therapy and administered according to the local label and standard clinical practice.
Study NCT00185614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: * Filgrastim 10 µg/kg/day to mobilize peripheral blood progenitor cells (PBPC) for autologous re-infusion (Auto-HCT)~* Filgrastim 5 µg/kg/day starting 6 days after melphalan (Day 4 after Auto-HCT)~* Filgrastim 16 µg/kg/day to mobilize donor peripheral blood progenitor cells (PBPC) for allogeneic transplant (Allo-HCT)
Study NCT00185614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan 200 mg/m2 (high-dose) intravenously as conditioning for Auto-HCT
Study NCT04626219 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imaging
Description: Imaging - Magnetic Resonance Imaging (MRI) scan of their heads
Study NCT00185614 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation (TBI)
Description: 200 centigray (cGy) total body irradiation delivered on Day 0
Study NCT04626219 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: fast
Description: hungry state - refrain from eating after lunch at 12 noon until 9 a.m. the next morning
Study NCT00185614 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CSP)
Description: Cyclosporine administered twice-daily by mouth at a dose of 6.25 mg/kg from Day -3 through Day 56
Study NCT00185614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil (MMF)
Description: Mycophenolate mofetil will begin at 15 mg/kg twice-daily by mouth from Day 0 to Day 27
Study NCT04626219 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: regulated meals
Description: standardized diet from noon until 9 a.m. the next day
Study NCT02096380 — intervention group
Intervention type: DRUG
Intervention: One cycle TPF induction chemotherapy for NPC
Description: One cycle TPF induction chemotherapy for NPC~Patients receive docetaxel (60mg/m2 on day 1), cisplatin (20mg/m2 on day 1-4) and fluorouracil (800mg/m2/d, continuous infusion, d1-4) every three weeks for single one cycle before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30mg/m2) every week for six cycles during radiotherapy.~A total dose of 70Gy in 30 fraction to PTV-P, 60Gy in 30 fraction to PTV-1 and 54Gy in 30 fraction to PTV-2.
Study NCT02096380 — intervention group
Intervention type: DRUG
Intervention: Three cycles TPF induction chemotherapy for NPC
Description: Three cycles TPF induction chemotherapy for NPC~Patients receive docetaxel (60mg/m2 on day 1), cisplatin (20mg/m2 on day 1-4) and fluorouracil (800mg/m2/d, continuous infusion, d1-4) every three weeks for three cycles before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30mg/m2) every week for six cycles during radiotherapy.~A total dose of 70Gy in 30 fraction to PTV-P, 60Gy in 30 fraction to PTV-1 and 54Gy in 30 fraction to PTV-2.
Study NCT04392362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adenosine
Description: A vial of adenosine with 6mg
Study NCT00059280 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Myozyme
Description: 20 mg/kg qow or 40mg/kg qow
Study NCT00432991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ephedrine [Synonyms: Ephedra, Ephedrinum]
Description: 25 mg, IM (in the muscle), one time
Study NCT00432991 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Description: 0.5 mL, IM (in the muscle), one time
Study NCT04445467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: Favipiravir
Study NCT04445467 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Favipiravir
Description: Favipiravir
Study NCT02225795 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplantation
Description: Immuno-ablative regimen for HSCT:~Day Treatment~* 6 r-ATG 2 mg/kg~* 5 r-ATG3 2 mg/kg~* 4 r-ATG3 2 mg/kg~* 3 Cyclophosphamide with Mesna~* 2 Cyclophosphamide with Mesna~* 1 REST 0 PBSC infusion~  * 3 Cyclophosphamide with Mesna~ * 4 Cyclophosphamide with Mesna~ * 6 Start GCSF
Study NCT00949065 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: intravenous immunoglobulins
Description: 0.36-0.44g/Kg IvIg intravenous, 3x, every 4 weeks
Study NCT00949065 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: intravenous immunoglobulins
Description: 0.36-0.44g/Kg IvIg intravenous, 3x, every 4 weeks
Study NCT02918630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: Participants will receive nicotine patch (21 mg) starting study Week 1. Participants will be instructed to apply a new patch each morning.
Study NCT02918630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Patch
Description: Participants will receive nicotine patch (21 mg) starting study Week 1. Participants will be instructed to apply a new patch each morning.
Study NCT02918630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E-cigarette
Description: The e-cigarette will consist of 1) a 3.3 V, 1000 mAh battery; and 2) a 1.5 Ohm, dual-coil cartomizer (SmokTech; Shenzhen, China). Study staff will load the cartomizer with 1 ml tobacco flavored 70% propylene glycol/30% vegetable glycerin liquid containing nicotine concentrations 36 mg/ml (AVAIL; Richmond, Virginia, USA).
Study NCT01807741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine
Description: Available in 5 and 10 mg.
Study NCT01807741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT03239054 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: pregnancy prescription for physical activity as part of prenatal care can increase healthy exercise behaviors during pregnancy
Study NCT03239054 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control group
Description: Information will be given as part of standard care
Study NCT03166358 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hatha yoga
Description: 8 Hatha yoga classes lasting approximately one hour each and delivered in small group format (i.e., classes no larger than 8 participants). Classes are tailored to address pediatric tension-type headache.
Study NCT02166593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin40mg/Fenofibrate160mg
Description: Pravafenix(Pravastatin40mg/Fenofibrate160mg)
Study NCT02166593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin40mg/Fenofibrate160mg
Description: Pravafenix(Pravastatin40mg/Fenofibrate160mg)
Study NCT02166593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin Sodium 10mg
Description: Lipitor 10mg(Atorvastatin Sodium)
Study NCT02166593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin Sodium 10mg
Description: Lipitor 10mg(Atorvastatin Sodium)
Study NCT02660424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-150
Study NCT05855278 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/MRI
Description: The participants receive 18F-FDG PET/MRI before and during definitive chemoradiotherapy.
Study NCT01755754 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Silicone Elastomer Vaginal Ring
Description: Silicone Elastomer Vaginal Ring
Study NCT01755754 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Female Condom
Description: Female condom
Study NCT01028560 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allergen extracts (subcutaneous injections)
Description: Allergy immunotherapy consists of regular subcutaneous injections of an individualized mixture of allergen extracts according to the allergy sensitization profile of each child. Increasing doses of allergen extract are given in 1-2 injections until a predetermined maintenance dose is reached. This maintenance dose varies by extract and accords to the general practice guidelines of immunotherapy. To increase safety, the cumulative monthly maintenance doses are divided into biweekly visits during the maintenance phase (year 2-3)
Study NCT01028560 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: standard of care asthma and allergy treatment
Study NCT01028560 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: standard of care asthma and allergy treatment
Study NCT01894646 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET) Imaging
Study NCT02660424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT01894646 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Positron Emission Tomography (PET) Imaging
Study NCT00941395 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Complete surveys
Study NCT04505787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esflurbiprofen hydrogel patch 165 mg (EFHP)
Description: patch application with PK blood sampling
Study NCT04505787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Froben 100 mg comprimidos revestidos
Description: tablet administration with PK blood sampling
Study NCT00814736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UK369,003
Description: oral tablet, once a day
Study NCT00814736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil
Description: single oral dose on day 14 or day 17
Study NCT00814736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil matching placebo
Description: single oral dose on day 14 or day 17
Study NCT04922879 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized lung rehabilitation
Description: Early respiratory function training, reasonable oxygen therapy to prevent hypoxemia, Positive pressure vibration training to promote coughing ability recovery, early exercise, Health education and psychological support.
Study NCT04332770 — intervention group
Intervention type: OTHER
Intervention: levothyroxine withdrawal
Description: All participants of this study are decided to get radioactive iodine therapy using levothyroxine withdrawal or human recombinant TSH injection prior to the study enrollment. That decision is independent with this study protocol. This study just collect continuous bio signals using wearable devices in the patients undergoing two different preparation methods for radioactive iodine therapy. That is why this study is an observational cohort study.
Study NCT01772771 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood, saliva/buccal swab samples
Study NCT01772771 — intervention group
Intervention type: OTHER
Intervention: Genetic Testing
Description: Correlative studies
Study NCT01772771 — intervention group
Intervention type: OTHER
Intervention: Medical Chart Review
Description: Review of medical records
Study NCT03743584 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Targeted temperature management
Description: Target temperature management at 33°C
Study NCT03743584 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard care, early treatment of fever
Description: Standard of care with early treatment of fever
Study NCT01793571 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP block
Description: 2 groups, group A a TAP block with 20 ml of Levobupivacaine 0,5% and subcutaneous wound infiltration with 20 ml sodium chloride (to blind patient and physician) and group B, TAP block with 20 ml sodium chloride and subcutaneous wound infiltration with 20 ml Levobupivacaine 0,5% (to blind patient and physician)
Study NCT01793571 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP block
Description: 2 groups, group A a TAP block with 20 ml of Levobupivacaine 0,5% and subcutaneous wound infiltration with 20 ml sodium chloride (to blind patient and physician) and group B, TAP block with 20 ml sodium chloride and subcutaneous wound infiltration with 20 ml Levobupivacaine 0,5% (to blind patient and physician)
Study NCT01773889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denileukin Diftitox/SC Pegylated IFNα-2a
Study NCT03997591 — intervention group
Intervention type: OTHER
Intervention: Ready2E.A.T. PROGRAM
Description: Training tasks based on:~reaching activities during attention tasks, memory tasks, sequential tasks This group was assessed at T0 and then after 6 weeks of conventional therapy.
Study NCT00416637 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab (Avastin)
Study NCT03397797 — intervention group
Intervention type: DRUG
Intervention: Rocuronium
Description: In the group to need the eletrophysiological monitoring during the operation, we don't inject muscle relaxant except anestheitic induction.
Study NCT02027688 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: q6 hour oral feeding schedule
Description: The intervention is the schedule under which stable infants are offered oral feeding attempts: every 6 hours.
Study NCT02027688 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: q3 hour oral feeding schedule
Description: The intervention is the schedule under which stable infants are offered oral feeding attempts: every 3 hours.
Study NCT00611455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ofatumumab
Description: 1000 mL dilution of 35ml of ofatumumab in sterile, pyrogen free 0.9% NaCl. Each Treatment Cycle consisting of two 700mg IV infusions taken 14 days apart. A total of 8 infusions cycles given over a 144 week period
Study NCT00611455 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1000 mL dilution of 35ml of ofatumumab in sterile, pyrogen free 0.9% NaCl. Each Treatment Cycle consisting of two IV infusions taken 14 days apart. Only one placebo treatment cycle provided over a 24 week period
Study NCT02676310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost
Study NCT04273295 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal massage
Description: The patients lying in comfortable relaxed supine position and physiotherapist performed slow circular clockwise movements on the abdomen, throw tangential pushing, with digital pulp, slow and gradual pressure, with fingers inclination 45 degree. The pressure applied to the abdomen on each point for 1 min, beginning with the ascending colon, transverse colon, descending colon and sigmoid; this sequence was repeated approximately 15 min. The therapist teaches the parents this technique and asked them to apply at home 3 times / day for 15 min.
Study NCT02520193 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Protocolized early mobilization in ICU